These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 34302857

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer.
    Labidi-Galy SI, Olivier T, Rodrigues M, Ferraioli D, Derbel O, Bodmer A, Petignat P, Rak B, Chopin N, Tredan O, Heudel PE, Stuckelberger S, Meeus P, Meraldi P, Viassolo V, Ayme A, Chappuis PO, Stern MH, Houdayer C, Stoppa-Lyonnet D, Buisson A, Golmard L, Bonadona V, Ray-Coquard I.
    Clin Cancer Res; 2018 Jan 15; 24(2):326-333. PubMed ID: 29084914
    [Abstract] [Full Text] [Related]

  • 3. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang W.
    JAMA Oncol; 2015 Jul 15; 1(4):486-94. PubMed ID: 26181259
    [Abstract] [Full Text] [Related]

  • 4. High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
    Hollis RL, Churchman M, Michie CO, Rye T, Knight L, McCavigan A, Perren T, Williams ARW, McCluggage WG, Kaplan RS, Jayson GC, Oza A, Harkin DP, Herrington CS, Kennedy R, Gourley C.
    Cancer; 2019 Aug 15; 125(16):2772-2781. PubMed ID: 31154673
    [Abstract] [Full Text] [Related]

  • 5. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
    Cohen S, Mosig R, Moshier E, Pereira E, Rahaman J, Prasad-Hayes M, Halpert R, Billaud JN, Dottino P, Martignetti JA.
    Gynecol Oncol; 2014 Sep 15; 134(3):591-8. PubMed ID: 24995581
    [Abstract] [Full Text] [Related]

  • 6. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
    Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS.
    J Ovarian Res; 2019 May 07; 12(1):40. PubMed ID: 31064392
    [Abstract] [Full Text] [Related]

  • 7. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
    Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W.
    J Natl Cancer Inst; 2015 Jul 07; 107(7):. PubMed ID: 25995442
    [Abstract] [Full Text] [Related]

  • 8. Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with BRCA mutated advanced high grade serous ovarian cancer: 10 year survival analysis.
    Kim SR, Parbhakar A, Li X, Bernardini MQ, Hogen L, May T.
    Int J Gynecol Cancer; 2024 Jun 03; 34(6):879-885. PubMed ID: 38548312
    [Abstract] [Full Text] [Related]

  • 9. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
    McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB.
    Mod Pathol; 2012 May 03; 25(5):740-50. PubMed ID: 22282309
    [Abstract] [Full Text] [Related]

  • 10. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
    Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W.
    JAMA; 2011 Oct 12; 306(14):1557-65. PubMed ID: 21990299
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U.
    Lancet Oncol; 2016 Nov 12; 17(11):1579-1589. PubMed ID: 27617661
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
    Weberpals JI, Pugh TJ, Marco-Casanova P, Goss GD, Andrews Wright N, Rath P, Torchia J, Fortuna A, Jones GN, Roudier MP, Bernard L, Lo B, Torti D, Leon A, Marsh K, Hodgson D, Duciaume M, Howat WJ, Lukashchuk N, Lazic SE, Whelan D, Sekhon HS.
    Cancer Med; 2021 May 12; 10(9):3045-3058. PubMed ID: 33811746
    [Abstract] [Full Text] [Related]

  • 18. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
    Mignogna C, Staropoli N, Botta C, De Marco C, Rizzuto A, Morelli M, Di Cello A, Franco R, Camastra C, Presta I, Malara N, Salvino A, Tassone P, Tagliaferri P, Barni T, Donato G, Di Vito A.
    J Ovarian Res; 2016 May 21; 9(1):31. PubMed ID: 27209210
    [Abstract] [Full Text] [Related]

  • 19. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, Reid J, Lanchbury JS, Darb-Esfahani S, Ganapathi MK, Sehouli J, Ganapathi RN.
    Br J Cancer; 2018 Oct 21; 119(9):1060-1066. PubMed ID: 30318511
    [Abstract] [Full Text] [Related]

  • 20. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
    Fransson Å, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N.
    J Ovarian Res; 2016 May 14; 9(1):27. PubMed ID: 27179933
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.